PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia

References

• Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307(5), 491–497 (2012).
   PubMed Web of Science ®Google Scholar
• Runge CF. Economic consequences of the obese. Diabetes 56(11), 2668–2672 (2007).
   PubMed Web of Science ®Google Scholar
• Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 89(6), 2595–2600 (2004).
   PubMed Web of Science ®Google Scholar
• Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444(7121), 881–887 (2006).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438), 937–952 (2004).
   PubMed Web of Science ®Google Scholar
• Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116(1), 39–48 (2007).
   PubMed Web of Science ®Google Scholar
• Despres JP. Cardiovascular disease under the influence of excess visceral fat. Crit. Pathw. Cardiol. 6(2), 51–59 (2007).
   PubMedGoogle Scholar
• Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. Med. Clin. North Am. 95(5), 893–902 (2011).
   PubMedGoogle Scholar
• Boekholdt SM, Arsenault BJ, Mora S et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 307(12), 1302–1309 (2012).
   PubMed Web of Science ®Google Scholar
• Rana JS, Boekholdt SM, Kastelein JJ, Shah PK. The role of non-HDL cholesterol in risk stratification for coronary artery disease. Curr. Atheroscler. Rep. 14(2), 130–134 (2012).
   Google Scholar
• Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28(7), 1225–1236 (2008).
   Web of Science ®Google Scholar
• Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. Curr. Opin. Lipidol. 17(3), 238–246 (2006).
   Google Scholar
• Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46(6), 733–749 (2003).
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Smilde TJ, Van WS et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 173(2), 261–267 (2004).
   Google Scholar
• Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology 132(6), 2181–2190 (2007).
   Google Scholar
• Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 32(9), 2104–2112 (2012).
   PubMed Web of Science ®Google Scholar
• Tan GD, Olivecrona G, Vidal H, Frayn KN, Karpe F. Insulin sensitisation affects lipoprotein lipase transport in Type 2 diabetes: role of adipose tissue and skeletal muscle in response to rosiglitazone. Diabetologia 49(10), 2412–2418 (2006).
   Google Scholar
• Cohn JS, Tremblay M, Batal R et al. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis 177(1), 137–145 (2004).
   Google Scholar
• Huang XS, Zhao SP, Hu M, Bai L, Zhang Q, Zhao W. Decreased apolipoprotein A5 is implicated in insulin resistance-related hypertriglyceridemia in obesity. Atherosclerosis 210(2), 563–568 (2010).
   Google Scholar
• Merkel M, Loeffler B, Kluger M et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J. Biol. Chem. 280(22), 21553–21560 (2005).
   Google Scholar
• Abifadel M, Varret M, Rabes JP et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34(2), 154–156 (2003).
   PubMed Web of Science ®Google Scholar
• Rashid S, Curtis DE, Garuti R et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl Acad. Sci. USA 102(15), 5374–5379 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354(12), 1264–1272 (2006).
   PubMed Web of Science ®Google Scholar
• Ouguerram K, Chetiveaux M, Zair Y et al. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler. Thromb. Vasc. Biol. 24(8), 1448–1453 (2004).
   PubMed Web of Science ®Google Scholar
• Herbert B, Patel D, Waddington SN et al. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler. Thromb. Vasc. Biol. 30(7), 1333–1339 (2010).
   PubMed Web of Science ®Google Scholar
• Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 94(7), 2537–2543 (2009).
   PubMed Web of Science ®Google Scholar
• Baass A, Dubuc G, Tremblay M et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin. Chem. 55(9), 1637–1645 (2009).
   PubMed Web of Science ®Google Scholar
• Cariou B, Langhi C, Le BM et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr. Metab. (Lond). 10(1), 4–10 (2013).
   PubMedGoogle Scholar
• Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl Acad. Sci. USA 101(18), 7100–7105 (2004).
   PubMed Web of Science ®Google Scholar
• Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279(48), 50630–50638 (2004).
   PubMed Web of Science ®Google Scholar
• Lambert G, Jarnoux AL, Pineau T et al. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology 147(10), 4985–4995 (2006).
   PubMed Web of Science ®Google Scholar
• Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler. Thromb. Vasc. Biol. 32(7), 1585–1595 (2012).
   PubMed Web of Science ®Google Scholar
• Gillian-Daniel DL, Bates PW, Tebon A, Attie AD. Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B. Proc. Natl Acad. Sci. USA 99(7), 4337–4342 (2002).
   Web of Science ®Google Scholar
• Blasiole DA, Oler AT, Attie AD. Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB. J. Biol. Chem. 283(17), 11374–11381 (2008).
   PubMed Web of Science ®Google Scholar
• Soutar AK. Unexpected roles for PCSK9 in lipid metabolism. Curr. Opin. Lipidol. 22(3), 192–196 (2011).
   Google Scholar
• Browning JD, Horton JD. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J. Lipid Res. 51(11), 3359–3363 (2010).
   PubMed Web of Science ®Google Scholar
• Ai D, Chen C, Han S et al. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J. Clin. Invest. 122(4), 1262–1270 (2012).
   PubMed Web of Science ®Google Scholar
• Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 409(6818), 307–312 (2001).
   PubMed Web of Science ®Google Scholar
• Steppan CM, Brown EJ, Wright CM et al. A family of tissue-specific resistin-like molecules. Proc. Natl Acad. Sci. USA 98(2), 502–506 (2001).
   PubMed Web of Science ®Google Scholar
• Qatanani M, Szwergold NR, Greaves DR, Ahima RS, Lazar MA. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J. Clin. Invest. 119(3), 531–539 (2009).
   Google Scholar
• Degawa-Yamauchi M, Bovenkerk JE, Juliar BE et al. Serum resistin (FIZZ3) protein is increased in obese humans. J. Clin. Endocrinol. Metab. 88(11), 5452–5455 (2003).
   PubMed Web of Science ®Google Scholar
• Vendrell J, Broch M, Vilarrasa N et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes. Res. 12(6), 962–971 (2004).
   PubMedGoogle Scholar
• Schaffler A, Buchler C, Muller-Ladner U et al. Identification of variables influencing resistin serum levels in patients with Type 1 and Type 2 diabetes mellitus. Horm. Metab. Res. 36(10), 702–707 (2004).
   PubMed Web of Science ®Google Scholar
• Azuma K, Katsukawa F, Oguchi S et al. Correlation between serum resistin level and adiposity in obese individuals. Obes. Res. 11(8), 997–1001 (2003).
   PubMedGoogle Scholar
• Piestrzeniewicz K, Luczak K, Komorowski J, Maciejewski M, Jankiewicz WJ, Goch JH. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metabolism 57(4), 488–493 (2008).
   Google Scholar
• Vozarova de Court, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 53(5), 1279–1284 (2004).
   Google Scholar
• Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J. Clin. Endocrinol. Metab. 88(4), 1730–1736 (2003).
   PubMedGoogle Scholar
• Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111(7), 932–939 (2005).
   PubMed Web of Science ®Google Scholar
• Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur. J. Endocrinol. 156(2), 279–284 (2007).
   PubMedGoogle Scholar
• Costandi J, Melone M, Zhao A, Rashid S. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ. Res. 108(6), 727–742 (2011).
   Google Scholar
• Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc. Med. 11(5), 170–176 (2001).
   PubMed Web of Science ®Google Scholar
• Melone M, Wilsie L, Palyha O, Strack A, Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J. Am. Coll. Cardiol. 59(19), 1697–1705 (2012).
   Google Scholar
• Fazio S, Linton MF. Proprotein convertase subtilisin/kexin type 9 as transducer of physiologic influences on cellular cholesterol: a case for resistin. J. Am. Coll. Cardiol. 59(19), 1706–1708 (2012).
   Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32(11), 1345–1361 (2011).
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol. 102(10 Suppl.), 1K–34K (2008).
   Google Scholar
• Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255–2267 (2011).
   PubMed Web of Science ®Google Scholar
• Matikainen N, Taskinen MR. Management of dyslipidemias in the presence of the metabolic syndrome or Type 2 diabetes. Curr. Cardiol. Rep. 14(6), 721–731 (2012).
   Google Scholar
• Wierzbicki AS, Clarke RE, Viljoen A, Mikhailidis DP. Triglycerides: a case for treatment? Curr. Opin. Cardiol. 27(4), 398–404 (2012).
   PubMed Web of Science ®Google Scholar
• Konig A, Bouzan C, Cohen JT et al. A quantitative analysis of fish consumption and coronary heart disease mortality. Am. J. Prev. Med. 29(4), 335–346 (2005).
   Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am. J. Cardiol. 108(5), 682–690 (2011).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am. J. Cardiol. 110(7), 984–992 (2012).
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lee RG, Bell TA, III et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ. Res. 112(11), 1479–1490 (2013).
   PubMed Web of Science ®Google Scholar
• Gaudet D, Methot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr. Opin. Lipidol. 23(4), 310–320 (2012).
   PubMed Web of Science ®Google Scholar
• Cuchel M, Rader DJ. Microsomal transfer protein inhibition in humans. Curr. Opin. Lipidol. 24(3), 246–250 (2013).
   PubMed Web of Science ®Google Scholar
• Costet P, Hoffmann MM, Cariou B, Guyomarc'h DB, Konrad T, Winkler K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 212(1), 246–251 (2010).
   Google Scholar
• Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. 367(20), 1891–1900 (2012).
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Desai NR, Kohli P et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 380(9858), 2007–2017 (2012).
   PubMed Web of Science ®Google Scholar
• King A. Lipids. Antibodies against PCSK9--a new era of therapy. Nat. Rev. Cardiol. 10(1), 1 (2013).
   Google Scholar
• Farnier M. PCSK9 inhibitors. Curr. Opin. Lipidol. 24(3), 251–258 (2013).
   Google Scholar
• Hooper AJ, Burnett JR. Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opin. Biol. Ther. 13(3), 429–435 (2013).
   PubMed Web of Science ®Google Scholar
• Duff CJ, Hooper NM. PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin. Ther. Targets 15(2), 157–168 (2011).
   PubMed Web of Science ®Google Scholar
• Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur. Heart J. 33(12), 1451–1458 (2012).
   PubMed Web of Science ®Google Scholar
• Lindholm MW, Elmen J, Fisker N et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol. Ther. 20(2), 376–381 (2012).
   PubMed Web of Science ®Google Scholar
• Gupta N, Fisker N, Asselin MC et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS ONE 5(5), e10682 (2010).
   PubMed Web of Science ®Google Scholar
• Frank-Kamenetsky M, Grefhorst A, Anderson NN et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl Acad. Sci. USA 105(33), 11915–11920 (2008).
   PubMed Web of Science ®Google Scholar
• Daquinag AC, Zhang Y, Amaya-Manzanares F, Simmons PJ, Kolonin MG. An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell. 9(1), 74–86 (2011).
   Google Scholar
• Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J. Am.Coll.Cardiol. 51(7), 724–730 (2008).
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115(4), 450–458 (2007).
   PubMed Web of Science ®Google Scholar